Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was upgraded by equities research analysts at Piper Jaffray Companies from a “neutral” rating to an “overweight” rating in a research note issued on Monday.

ARWR has been the subject of a number of other reports. Jefferies Group LLC reaffirmed a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, September 25th. Finally, William Blair raised shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $2.00.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $3.70 on Monday. Arrowhead Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $4.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.84 and a quick ratio of 3.84.

A number of hedge funds have recently made changes to their positions in ARWR. Bank of New York Mellon Corp increased its holdings in Arrowhead Pharmaceuticals by 3.7% during the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after buying an additional 11,099 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 53,500 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 21,654 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $467,000. Finally, Virtu KCG Holdings LLC increased its stake in shares of Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares in the last quarter. 21.44% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/arrowhead-pharmaceuticals-inc-arwr-rating-increased-to-overweight-at-piper-jaffray-companies/1728715.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.